{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T08:26:06Z","timestamp":1763713566970,"version":"3.45.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor T-cell (CAR-T) therapy has shown remarkable efficacy in treating relapsed\/refractory B-cell malignancies, as supported by real-world evidence (RWE). However, limited RWE exists on the management of adverse events during the perioperative period following CAR-T infusion. This study was conducted to obtain RWE on perioperative management using the Japanese Diagnosis Procedure Combination database, a comprehensive repository of Japanese health and medical service data. Between November 2019 and March 2022, 388 patients received CAR-T therapy. Of these, 312 had large B-cell lymphoma (LBCL) and 76 had B-cell acute lymphoblastic leukemia (B-ALL). The number of CAR-T infusions increased every 6-month interval, correlating with the rise in LBCL cases. Tocilizumab was administered for cytokine release syndrome in 56.1% of LBCL and 42.1% of B-ALL patients. Steroids were used for 22.9% and 81.3%, respectively. Prophylaxis for fungal infections was administered during CAR-T infusion in most LBCL and B-ALL patients. Treatment intensity was escalated in 2.8% of LBCL and 7.0% of B-ALL patients, and treatment for cytomegalovirus infection was initiated in approximately 7% of patients. This analysis elucidated perioperative management strategies based on patients\u2019 medication histories.<\/jats:p>","DOI":"10.1007\/s12185-025-04043-8","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T18:36:59Z","timestamp":1754505419000},"page":"856-863","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of inpatient chimeric antigen receptor T-cell therapy for relapsed\/refractory B-cell malignancies: an analysis using the Japanese Diagnosis Procedure Combination database"],"prefix":"10.1007","volume":"122","author":[{"given":"Keisuke","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Umezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohide","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3142-8806","authenticated-orcid":false,"given":"Masahide","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"issue":"1","key":"4043_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"5","key":"4043_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"26","key":"4043_CR3","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"10254","key":"4043_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"1","key":"4043_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3324\/haematol.2022.280805","volume":"108","author":"M Kwon","year":"2023","unstructured":"Kwon M, Iacoboni G, Reguera JL, Corral LL, Morales RH, Ortiz-Maldonado V, et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2023;108(1):110\u201321.","journal-title":"Haematologica"},{"issue":"10","key":"4043_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","volume":"28","author":"PA Riedell","year":"2022","unstructured":"Riedell PA, Hwang WT, Nastoupil LJ, Pennisi M, McGuirk JP, Maziarz RT, et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas. Transplant Cell Ther. 2022;28(10):669\u201376.","journal-title":"Transplant Cell Ther"},{"issue":"20","key":"4043_CR7","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1182\/bloodadvances.2023012549","volume":"8","author":"N Ahmed","year":"2024","unstructured":"Ahmed N, Wesson W, Lutfi F, Porter DL, Bachanova V, Nastoupil LJ, et al. Optimizing the post-CAR T monitoring period for axicabtagene ciloleucel, tisagenlecleucel, and Lisocabtagene maraleucel. Blood Adv. 2024;8(20):5346\u201354.","journal-title":"Blood Adv"},{"issue":"11","key":"4043_CR8","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","volume":"7","author":"P Bader","year":"2023","unstructured":"Bader P, Rossig C, Hutter M, Ayuk FA, Baldus CS, B\u00fccklein VL, et al. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany. Blood Adv. 2023;7(11):2436\u201348.","journal-title":"Blood Adv"},{"issue":"10","key":"4043_CR9","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28(10):2145\u201354.","journal-title":"Nat Med"},{"issue":"4","key":"4043_CR10","first-page":"349","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, Tresckow BV, et al. GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022;140(4):349\u201358.","journal-title":"Blood"},{"issue":"9","key":"4043_CR11","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1080\/10428194.2022.2060503","volume":"63","author":"RT Maziarz","year":"2022","unstructured":"Maziarz RT, Yang H, Liu Q, Wang T, Zhao J, Lim S, et al. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States. Leuk Lymphoma. 2022;63(9):2052\u201362.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"4043_CR12","doi-asserted-by":"publisher","first-page":"404.e1","DOI":"10.1016\/j.jtct.2022.03.021","volume":"28","author":"SJ Keating","year":"2022","unstructured":"Keating SJ, Gu T, Jun MP, McBride A. Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States. Transplant Cell Ther. 2022;28(7):404.e1-e6.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"4043_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2188\/jea.JE20200288","volume":"31","author":"K Hayashida","year":"2021","unstructured":"Hayashida K, Murakami G, Matsuda S, Fushimi K. History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan. J Epidemiol. 2021;31(1):1\u201311.","journal-title":"J Epidemiol"},{"issue":"4","key":"4043_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4043_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33(3):259\u201375.","journal-title":"Ann Oncol"},{"issue":"6","key":"4043_CR16","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41409-024-02248-9","volume":"59","author":"JR Passweg","year":"2024","unstructured":"Passweg JR, Baldomero H, Ciceri F, de la Camara R, Glass B, Greco R, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transplant. 2024;59(6):803\u201312.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"4043_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","volume":"31","author":"ST Spellman","year":"2025","unstructured":"Spellman ST, Xu K, Oloyede T, Ahn KW, Akhtar O, Bolon YT, et al. Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy \u2013 a report from the CIBMTR. Transplant Cell Ther. 2025;31(8):505\u2013532","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"4043_CR18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bjh.18209","volume":"198","author":"A Kuhnl","year":"2022","unstructured":"Kuhnl A, Roddie C, Kirkwood AA, Tholouli E, Menne T, Patel A, et al. A national service for delivering CD19 CAR-Tin large B-cell lymphoma\u2014the UK real-world experience. Br J Haematol. 2022;198(3):492\u2013502.","journal-title":"Br J Haematol"},{"issue":"10","key":"4043_CR19","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1002\/cam4.3881","volume":"10","author":"G Iacoboni","year":"2021","unstructured":"Iacoboni G, Villacampa G, Martinez-Cibrian N, Bailen R, Corral LL, Sanchez JM, et al. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Med. 2021;10(10):3214\u201323.","journal-title":"Cancer Med"},{"issue":"11","key":"4043_CR20","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ajh.25951","volume":"95","author":"P Sesques","year":"2020","unstructured":"Sesques P, Ferrant E, Safar V, Wallet F, Tordo J, Dhomps A, et al. Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center. Am J Hematol. 2020;95(11):1324\u201333.","journal-title":"Am J Hematol"},{"issue":"6","key":"4043_CR21","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s10147-023-02334-w","volume":"28","author":"H Goto","year":"2023","unstructured":"Goto H, Kitawaki T, Fujii N, Kato K, Onishi Y, Fukuhara N, et al. Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan. Int J Clin Oncol. 2023;28(6):816\u201326.","journal-title":"Int J Clin Oncol"},{"issue":"21","key":"4043_CR22","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414\u201324.","journal-title":"Blood Adv"},{"issue":"9","key":"4043_CR23","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.20.03585","volume":"40","author":"LM Schultz","year":"2022","unstructured":"Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, et al. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial Tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol. 2022;40(9):945\u201355.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4043_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jtct.2024.11.016","volume":"31","author":"I Kato","year":"2025","unstructured":"Kato I, Tomizawa D, Kato M, Hirabayashi S, Manabe A, Irie M, et al. Real-world outcomes of commercial Tisagenlecleucel for children, adolescents, and young adults with acute lymphoblastic leukemia in Japan. Transplant Cell Ther. 2025;31(2):86\u201396.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"4043_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/ejh.13712","volume":"108","author":"O Beyar-Katz","year":"2022","unstructured":"Beyar-Katz O, Kikozashvili N, Bar On Y, Amit O, Perry C, Avivi I, et al. Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells. Eur J Haematol. 2022;108(1):52\u201360.","journal-title":"Eur J Haematol"},{"issue":"10","key":"4043_CR26","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","volume":"30","author":"Z Shahid","year":"2024","unstructured":"Shahid Z, Jain T, Dioverti V, Pennisi M, Mikkilineni L, Thiruvengadam SK, et al. Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies. Transplant Cell Ther. 2024;30(10):955\u201369.","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"4043_CR27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3324\/haematol.2022.281719","volume":"108","author":"G Chen","year":"2023","unstructured":"Chen G, Herr M, Nowak J, Ho C, Almyroudis N, Attwood K, et al. Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. Haematologica. 2023;108(2):615\u201320.","journal-title":"Haematologica"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04043-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04043-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04043-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T08:23:43Z","timestamp":1763713423000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04043-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4043"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04043-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"13 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Keisuke Tanaka reports honoraria from Novartis. Yoshihiro Umezawa reports honoraria from Novartis. Takehiko Mori reports honoraria from Novartis, Daiichi Sankyo, Bristol-Myers Squibb. Masahide Yamamoto reports honoraria from Novartis, Bristol-Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent were waived because this was retrospective study using the databese of Japanese medical and health service and there was a minimal risk to participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}}]}}